BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 21816821)

  • 21. A bacteriolytic agent that detects and kills Bacillus anthracis.
    Schuch R; Nelson D; Fischetti VA
    Nature; 2002 Aug; 418(6900):884-9. PubMed ID: 12192412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel
    Cater K; Dandu VS; Bari SM; Lackey K; Everett GF; Hatoum-Aslan A
    mSphere; 2017; 2(2):. PubMed ID: 28357414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The bifunctional cell wall hydrolase CwlT is needed for conjugation of the integrative and conjugative element ICEBs1 in Bacillus subtilis and B. anthracis.
    DeWitt T; Grossman AD
    J Bacteriol; 2014 Apr; 196(8):1588-96. PubMed ID: 24532767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of the catalytic activity of the gamma-phage lysin, PlyG, specific for Bacillus anthracis.
    Kikkawa HS; Ueda T; Suzuki S; Yasuda J
    FEMS Microbiol Lett; 2008 Sep; 286(2):236-40. PubMed ID: 18662316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of the amino acid residues critical for specific binding of the bacteriolytic enzyme of gamma-phage, PlyG, to Bacillus anthracis.
    Kikkawa H; Fujinami Y; Suzuki S; Yasuda J
    Biochem Biophys Res Commun; 2007 Nov; 363(3):531-5. PubMed ID: 17888883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deciphering how Cpl-7 cell wall-binding repeats recognize the bacterial peptidoglycan.
    Bustamante N; Iglesias-Bexiga M; Bernardo-García N; Silva-Martín N; García G; Campanero-Rhodes MA; García E; Usón I; Buey RM; García P; Hermoso JA; Bruix M; Menéndez M
    Sci Rep; 2017 Nov; 7(1):16494. PubMed ID: 29184076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mutant bacteriophage evolved to infect resistant bacteria gained a broader host range.
    Habusha M; Tzipilevich E; Fiyaksel O; Ben-Yehuda S
    Mol Microbiol; 2019 Jun; 111(6):1463-1475. PubMed ID: 30811056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant bacteriophage lysins as antibacterials.
    Fenton M; Ross P; McAuliffe O; O'Mahony J; Coffey A
    Bioeng Bugs; 2010; 1(1):9-16. PubMed ID: 21327123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystal and cryoEM structural studies of a cell wall degrading enzyme in the bacteriophage phi29 tail.
    Xiang Y; Morais MC; Cohen DN; Bowman VD; Anderson DL; Rossmann MG
    Proc Natl Acad Sci U S A; 2008 Jul; 105(28):9552-7. PubMed ID: 18606992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LysA2, the Lactobacillus casei bacteriophage A2 lysin is an endopeptidase active on a wide spectrum of lactic acid bacteria.
    Ribelles P; Rodríguez I; Suárez JE
    Appl Microbiol Biotechnol; 2012 Apr; 94(1):101-10. PubMed ID: 21952940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacteriophage lysins as effective antibacterials.
    Fischetti VA
    Curr Opin Microbiol; 2008 Oct; 11(5):393-400. PubMed ID: 18824123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of high-affinity cell wall-binding domains of bacteriophage endolysins for immobilization and separation of bacterial cells.
    Kretzer JW; Lehmann R; Schmelcher M; Banz M; Kim KP; Korn C; Loessner MJ
    Appl Environ Microbiol; 2007 Mar; 73(6):1992-2000. PubMed ID: 17277212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CELL-WALL LYSINS OF STAPHYLOCOCCUS AUREUS STRAINS INDUCED BY SPECIFIC TYPING PHAGES.
    RALSTON DJ; MCIVOR M
    J Bacteriol; 1964 Sep; 88(3):667-75. PubMed ID: 14208505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections.
    Gondil VS; Harjai K; Chhibber S
    Int J Antimicrob Agents; 2020 Feb; 55(2):105844. PubMed ID: 31715257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of the Bacillus anthracis (gamma) phage receptor.
    Davison S; Couture-Tosi E; Candela T; Mock M; Fouet A
    J Bacteriol; 2005 Oct; 187(19):6742-9. PubMed ID: 16166537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EC300: a phage-based, bacteriolysin-like protein with enhanced antibacterial activity against Enterococcus faecalis.
    Proença D; Leandro C; Garcia M; Pimentel M; São-José C
    Appl Microbiol Biotechnol; 2015 Jun; 99(12):5137-49. PubMed ID: 25728445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific Isolation of
    Zhang Z; Douillard FP; Korkeala H; Lindström M
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955526
    [No Abstract]   [Full Text] [Related]  

  • 38. Characterization of modular bacteriophage endolysins from Myoviridae phages OBP, 201φ2-1 and PVP-SE1.
    Walmagh M; Briers Y; dos Santos SB; Azeredo J; Lavigne R
    PLoS One; 2012; 7(5):e36991. PubMed ID: 22615864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interrogation of the contribution of (endo)lysin domains to tune their bacteriolytic efficiency provides a novel clue to design superior antibacterials.
    Gallego-Páramo C; Hernández-Ortiz N; García P; Menéndez M
    Int J Biol Macromol; 2022 Dec; 223(Pt A):1042-1053. PubMed ID: 36370862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New bacteriophage-derived lysins, LysJ and LysF, with the potential to control Bacillus anthracis.
    Nakonieczna A; Topolska-Woś A; Łobocka M
    Appl Microbiol Biotechnol; 2024 Dec; 108(1):76. PubMed ID: 38194144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.